Bill et al. investigated the mutational status in 96 de novo AML patients with KMT2A gene rearrangement and found that 32% of patients had mutations in genes constituting the RAS signaling pathway (NRAS, KRAS, and PTPN11) [11]. The gene discussed is KRAS; the disease is acute myeloid leukemia.